Payment overview · 2025
General Payments
$916.36
45 reported records · 17 companies
Healthcare provider profile · identity verified
David L Seaton, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SOMERVILLE, TN · NPI 1487748745
Verified facts
What the public records show
CMS Open Payments records show David L Seaton, MD received $916.36 in general payments during 2025 across 45 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Qulipta, Rybelsus, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 435 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 277 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $197.67 | 21.6% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $113.05 | 12.3% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $90.60 | 9.9% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $85.06 | 9.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.93 | 8.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $65.34 | 7.1% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.49 | 3.8% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.97 | 3.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.41 | 3.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.83 | 3.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.16 | 3.2% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $26.58 | 2.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.87 | 2.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $22.73 | 2.5% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $22.17 | 2.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.33 | 2.1% | 1 | 2025 |
| Athena Bioscience, LLC | Unresolved — no canonical attribution shown | $19.17 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $916.36 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $117.81 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $107.57 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $92.57 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $90.60 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $65.34 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.97 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.17 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.16 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.35 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $32.97 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.41 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.41 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.83 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.16 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $26.58 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $26.58 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| NEXICLON XR Normalized: nexiclon xr |
Drug | Athena Bioscience, LLC | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 163 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 435 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 277 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 79 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 215 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
61 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
192 | 53 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
163 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
98 | 98 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
76 | 59 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
215 | 50 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
163 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
435 | 65 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
86 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
277 | 60 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
79 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1030 | 277 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1006 | 255 |
| Gabapentin | Gabapentin | 755 | 158 |
| Losartan Potassium | Losartan Potassium | 677 | 178 |
| Omeprazole | Omeprazole | 655 | 174 |
| Alprazolam | Alprazolam | 611 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 543 | 140 |
| Pantoprazole Sodium | Pantoprazole Sodium | 542 | 122 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 531 | 85 |
| Lisinopril | Lisinopril | 518 | 141 |
| Potassium Chloride | Potassium Chloride | 504 | 139 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 493 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 486 | 142 |
| Furosemide | Furosemide | 466 | 120 |
| Mounjaro | Tirzepatide | 435 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 431 | 109 |
| Metformin Hcl | Metformin Hcl | 415 | 127 |
| Tamsulosin Hcl | Tamsulosin Hcl | 412 | 101 |
| Eliquis | Apixaban | 389 | 59 |
| Carvedilol | Carvedilol | 381 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 375 | 111 |
| Simvastatin | Simvastatin | 327 | 95 |
| Escitalopram Oxalate | Escitalopram Oxalate | 322 | 63 |
| Allopurinol | Allopurinol | 308 | 70 |
| Clopidogrel | Clopidogrel Bisulfate | 300 | 67 |
| Trazodone Hcl | Trazodone Hcl | 294 | 78 |
| Ozempic | Semaglutide | 277 | 60 |
| Clonazepam | Clonazepam | 262 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 262 | 74 |
| Famotidine | Famotidine | 239 | 63 |
| Meloxicam | Meloxicam | 231 | 76 |
| Zolpidem Tartrate | Zolpidem Tartrate | 221 | 37 |
| Promethazine Hcl | Promethazine Hcl | 220 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 219 | 48 |
| Glimepiride | Glimepiride | 215 | 61 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 215 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 211 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 63 |
| Montelukast Sodium | Montelukast Sodium | 203 | 56 |
| Prednisone | Prednisone | 200 | 99 |
| Sertraline Hcl | Sertraline Hcl | 198 | 52 |
| Farxiga | Dapagliflozin Propanediol | 192 | 53 |
| Tramadol Hcl | Tramadol Hcl | 187 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 174 | 41 |
| Oxycodone Hcl | Oxycodone Hcl | 170 | 23 |
| Jardiance | Empagliflozin | 163 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 163 | 39 |
| Atenolol | Atenolol | 158 | 41 |
| Buspirone Hcl | Buspirone Hcl | 156 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 156 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 153 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 151 | 27 |
| Pregabalin | Pregabalin | 144 | 24 |
| Lorazepam | Lorazepam | 138 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 34 |
| Metformin Hcl Er | Metformin Hcl | 134 | 41 |
| Ezetimibe | Ezetimibe | 131 | 37 |
| Celecoxib | Celecoxib | 128 | 45 |
| Diazepam | Diazepam | 128 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 122 | 32 |
| Spironolactone | Spironolactone | 121 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 120 | 22 |
| Januvia | Sitagliptin Phosphate | 119 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 118 | 38 |
| Clonidine Hcl | Clonidine Hcl | 107 | 33 |
| Lovastatin | Lovastatin | 106 | 34 |
| Finasteride | Finasteride | 102 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 101 | 24 |
| Ondansetron Odt | Ondansetron | 99 | 37 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 98 | 98 |
| Meclizine Hcl | Meclizine Hcl | 95 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 95 | 37 |
| Donepezil Hcl | Donepezil Hcl | 93 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 38 |
| Topiramate | Topiramate | 91 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 89 | 21 |
| Amoxicillin | Amoxicillin | 87 | 68 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 86 | 33 |
| Methocarbamol | Methocarbamol | 86 | 34 |
| Trulicity | Dulaglutide | 86 | 27 |
| Alendronate Sodium | Alendronate Sodium | 85 | 25 |
| Xarelto | Rivaroxaban | 85 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 81 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 80 | 25 |
| Cephalexin | Cephalexin | 79 | 60 |
| Rybelsus | Semaglutide | 79 | 19 |
| Torsemide | Torsemide | 77 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 76 | 59 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 75 | 57 |
| Warfarin Sodium | Warfarin Sodium | 75 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 20 |
| Baclofen | Baclofen | 71 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 20 |
| Levetiracetam | Levetiracetam | 70 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 69 | 16 |
| Fluconazole | Fluconazole | 67 | 47 |
| Chlorthalidone | Chlorthalidone | 66 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 65 | 11 |
| Glipizide | Glipizide | 65 | 21 |
| Ibuprofen | Ibuprofen | 65 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 18 |
| Ramipril | Ramipril | 65 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 64 | 13 |
| Azithromycin | Azithromycin | 62 | 49 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 62 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 61 | 17 |
| Linzess | Linaclotide | 61 | 18 |
| Colestipol Hcl | Colestipol Hcl | 60 | suppressed |
| Estradiol | Estradiol | 59 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 58 | 13 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 58 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 57 | 19 |
| Aripiprazole | Aripiprazole | 55 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 55 | 23 |
| Entresto | Sacubitril/Valsartan | 53 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | suppressed |
| Nitroglycerin | Nitroglycerin | 51 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 18 |
| Nifedipine Er | Nifedipine | 49 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 49 | suppressed |
| Levofloxacin | Levofloxacin | 48 | 35 |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 33 |
| Varenicline Tartrate | Varenicline Tartrate | 45 | 12 |
| Nystatin | Nystatin | 44 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 36 |
| Calcitriol | Calcitriol | 42 | suppressed |
| Primidone | Primidone | 41 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 39 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | 15 |
| Carisoprodol | Carisoprodol | 37 | suppressed |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 11 |
| Dutasteride | Dutasteride | 35 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 35 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | suppressed |
| Ranolazine Er | Ranolazine | 34 | suppressed |
| Clonidine | Clonidine | 33 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 33 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Valsartan | Valsartan | 32 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Belsomra | Suvorexant | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Cefdinir | Cefdinir | 27 | 24 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Vraylar | Cariprazine Hcl | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Lacosamide | Lacosamide | 24 | suppressed |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 23 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 23 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 23 | 22 |
| Trintellix | Vortioxetine Hydrobromide | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Indapamide | Indapamide | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 15 |
| Haloperidol | Haloperidol | 21 | suppressed |
| Nabumetone | Nabumetone | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Invokana | Canagliflozin | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 12 |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Topamax | Topiramate | 13 | suppressed |
| Tri-Vylibra | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $916.36 · 45 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, Fluad, Flucelvax, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NEXICLON XR, NUPLAZID, Omnipod, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Wegovy, ZENPEP, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error